What is a stock summary page? Click here for an overview.
Business Description
Theravance Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : KYG8807B1068
Compare
Compare
Traded in other countries / regions
TBPH.USA0TB.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-05-16Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.77 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -1.3 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.1 | |||||
| Beneish M-Score | -0.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.3 | |||||
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 54.6 | |||||
| 3-Year FCF Growth Rate | 56.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -32.02 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.53 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.45 | |||||
| 9-Day RSI | 36.9 | |||||
| 14-Day RSI | 41.82 | |||||
| 3-1 Month Momentum % | -1.72 | |||||
| 6-1 Month Momentum % | 12.96 | |||||
| 12-1 Month Momentum % | -1.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.02 | |||||
| Quick Ratio | 5.02 | |||||
| Cash Ratio | 2.75 | |||||
| Days Sales Outstanding | 92.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 12.7 | |||||
| Shareholder Yield % | 1.44 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -65.91 | |||||
| Net Margin % | -87.63 | |||||
| FCF Margin % | -18.43 | |||||
| ROE % | -29 | |||||
| ROA % | -15.45 | |||||
| ROIC % | -21.47 | |||||
| 3-Year ROIIC % | 218.51 | |||||
| ROC (Joel Greenblatt) % | -91.05 | |||||
| ROCE % | -12.37 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 281.59 | |||||
| PS Ratio | 6.69 | |||||
| PB Ratio | 2.47 | |||||
| Price-to-Tangible-Book | 2.47 | |||||
| EV-to-EBIT | -9.68 | |||||
| EV-to-EBITDA | -10.59 | |||||
| EV-to-Revenue | 6.32 | |||||
| EV-to-Forward-Revenue | 4.24 | |||||
| EV-to-FCF | -34.31 | |||||
| Price-to-GF-Value | 0.51 | |||||
| Price-to-Median-PS-Value | 0.43 | |||||
| Earnings Yield (Greenblatt) % | -10.33 | |||||
| FCF Yield % | -2.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TBPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theravance Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 64.381 | ||
| EPS (TTM) ($) | -1.15 | ||
| Beta | -0.12 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 31.89 | ||
| 14-Day RSI | 41.82 | ||
| 14-Day ATR ($) | 0.317258 | ||
| 20-Day SMA ($) | 9.311 | ||
| 12-1 Month Momentum % | -1.51 | ||
| 52-Week Range ($) | 7.44 - 10.9 | ||
| Shares Outstanding (Mil) | 49.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theravance Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theravance Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theravance Biopharma Inc Frequently Asked Questions
What is Theravance Biopharma Inc(TBPH)'s stock price today?
The current price of TBPH is $8.76. The 52 week high of TBPH is $10.90 and 52 week low is $7.44.
When is next earnings date of Theravance Biopharma Inc(TBPH)?
The next earnings date of Theravance Biopharma Inc(TBPH) is 2025-05-13 Est..
Does Theravance Biopharma Inc(TBPH) pay dividends? If so, how much?
Theravance Biopharma Inc(TBPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers